[Receptor mechanisms underlying the modulation of lipopolysaccharide-induced nuclear factor-kappaB expression in vascular endothelial cells by cholecystokinin octapeptide].
To elucidate the receptor mechanisms underlying the modulation of lipopolysaccharide (LPS)-induced nuclear factor-kappaB (NF-kappaB) expression in human umbilical vein endothelial cell line ECV-304 cells by cholecystokinin octapeptide (CCK-8). Human umbilical vein endothelial cell line ECV-304 cells were stimulated with vehicle, LPS, CCK-8 (10(-9)-10(-7) mol/L), CCK receptor non-specific antagonist proglumide, CCK-A receptor (CCK-AR) specific antagonist CR-1409 or CCK-B receptor (CCK-BR) specific antagonist CR-2945 singularly or in combination. The NF-kappaB p65 protein level was determined by Western blot and immunocytochemistry technique. LPS resulted in an increase in the up-regulatory expression and nuclear translocation of NF-kappaB p65 protein in ECV-304 compared with vehicle stimulation. CCK-8 obviously inhibited LPS-induced the changes in NF-kappaB p65 protein in a dose-dependent manner. The inhibitory effects of CCK-8 on NF-kappaB p65 protein expression were attenuated by proglumide>CR-2945>CR-1409. CCK-AR and CCK-BR are involved in the mediation of CCK-8 inhibitive regulation for LPS-induced NF-kappaB protein expression in ECV-04 cells, whereas the effect of CCK-BR are more than that of CCK-R.